CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
CareDx in the News
April 13, 2018
April 11, 2018
March 30, 2018
Information on CareDx
Learn about AlloSure
AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
Learn about AlloMap
AlloMap is a non-invasive blood test that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.
Upcoming Events
Look for CareDx at the following 2018 events:
ISHLT 38th Annual Meeting 2018
Nice, France
April 11-14, 2018
EFI 32nd Annual Meeting 2018
Venice, Italy
May 9-12, 2018
ATC 2018
Seattle, WA, United States
June 2-6, 2018
ASHI 44th Annual Meeting 2018
Baltimore, MD, United States
October 1-5, 2018